Mi Li
Impact in
-
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
-
- Hippo pathway signaling and YAP/TAZ
Papers in
-
- Epigenetics and DNA Methylation 6
- Renal and related cancers 2
-
- Cancer-related molecular mechanisms research 2
- Cancer, Hypoxia, and Metabolism 2
- Co-authors
- Xin Jin (3 shared papers)Caihong Yang (6 shared papers)Xiaojuan Li (4 shared papers)Fengjing Guo (3 shared papers)Zengwu Shao (1 shared paper)Wei Wu (1 shared paper)Xingzhi Jing (1 shared paper)Jingyuan Chen (1 shared paper)
In The Last Decade
Mi Li
13 papers receiving 196 citations
Peers
Comparison fields: 5 of 57
- Cancer Research 57
- Cell Biology 26
- Rheumatology 21
- Molecular Biology 86
- Oncology 30
Countries citing papers authored by Mi Li
This map shows the geographic impact of Mi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mi Li more than expected).
Fields of papers citing papers by Mi Li
This network shows the impact of papers produced by Mi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mi Li. The network helps show where Mi Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Mi Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 43 | |
| 2 | USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1. | 2019 | 34 |
| 3 | 2021 | 24 | |
| 4 | 2020 | 20 | |
| 5 | 2020 | 17 | |
| 6 | 2021 | 13 | |
| 7 | 2017 | 10 | |
| 8 | 2017 | 9 | |
| 9 | 2021 | 8 | |
| 10 | 2024 | 7 | |
| 11 | 2024 | 5 | |
| 12 | 2023 | 5 | |
| 13 | 2023 | 2 | |
| 14 | 2025 | 0 | |
| 15 | 2021 | 0 | |
| 16 | 2025 | 0 |
About Mi Li
Mi Li is a scholar working on Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine, Oncology and Cell Biology, having authored 16 papers that have together received 197 indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (6 papers), Ferroptosis and cancer prognosis (2 papers), Renal cell carcinoma treatment (2 papers), Renal and related cancers (2 papers), Cancer-related molecular mechanisms research (2 papers), Cancer, Hypoxia, and Metabolism (2 papers), Clay minerals and soil interactions (1 paper) and Recycling and Waste Management Techniques (1 paper). The work is most often cited by research in Cancer Research (57 citations), Cell Biology (26 citations), Rheumatology (21 citations), Molecular Biology (86 citations) and Oncology (30 citations). Mi Li has collaborated with scholars based in China, Japan and Australia. Frequent co-authors include Xin Jin, Caihong Yang, Xiaojuan Li, Fengjing Guo, Zengwu Shao, Wei Wu, Xingzhi Jing, Jingyuan Chen, Ping Fan and Shikai Zhu. Their work appears in journals such as Aging, IEEE/ACM Transactions on Computational Biology and Bioinformatics, ACS Omega, Journal of Surgical Oncology and International Journal of Molecular Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.